Book a Meeting

Non-Fucosylated Anti-Human FZD5 (18R8) Therapeutic Antibody (CAT#: BioBet-1440ZP) Datasheet

Target
FZD5
Isotype
IgG
Description
ADCC-Enhanced anti-FZD5 (18R8) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced FZD5 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FZD5
Full Name
Frizzled-5
Background
Frizzled-5 is a protein that in humans is encoded by the FZD5 gene.
Alternative Names
FZD5, C2orf31, HFZ5, frizzled class receptor 5
Gene ID
7855
Cellular Localization
Golgi apparatus, Plasma membrane
Involvement in Disease
Diseases associated with FZD5 include Coloboma Of Macula and Coloboma Of Eyelid.
Related Pathways
Its related pathways are Regulation of activated PAK-2p34 by proteasome mediated degradation and Association Between Physico-Chemical Features and Toxicity Associated Pathways.
Function
Wnt protein receptor. Can activate WNT2, WNT10B, WNT5A, but WNT2B, WNT4 are not activated (in vitro); the situation may be different in vivo, because not all of these are known to be expressed together (by similarity). In neurons, the activation of WNT7A promotes the formation of synapses. Play a role in the typical Wnt/ -catenin signaling pathway. The typical Wnt/-catenin signaling pathway leads to the activation of scrambled proteins, the inhibition of GSK-3 kinase, the nuclear accumulation of -catenin and the activation of Wnt target genes (through similarity). A second signaling pathway involving PKC and calcium flux has been found in some family members, but it is not clear whether it represents a unique pathway or whether it can be integrated into the canonical pathway because of Wnt-mediated GSK-3 Kinase inactivation seems to require PKC. Both of these pathways seem to involve interaction with protein g. It may be involved in the formation of tissue morphology and/or the transduction of polarity information and cell-to-cell transmission in differentiated tissues (possibly). It plays a role in yolk sac angiogenesis and placental angiogenesis (similar).
Post-translational modifications
1.Ubiquitinated by RNF43 and ZNRF3, leading to its degradation by the proteasome 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn47 and Asn151
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
18R8
Host
Human
Species Reactivity
Human
Description
The antibody binds to human frizzled receptor and confirmed to inhibit Wnt signaling and/or inhibit tumor growth.
Indication
Cancer

Cancer

Related Products

Non-Fucosylated Anti-Human FZD5 (18R5) Therapeutic Antibody (CAT#: BioBet-1441ZP)
Non-Fucosylated Anti-Human FZD5 (44R24) Therapeutic Antibody (CAT#: BioBet-1442ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.